Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study

Diabetes Therapy

Volumn 6, Issue 4, 2015, Pages 559-571

  Hirose, Takahisa ^a   Suzuki, Manabu ^b   Tsumiyama, Isao ^b  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Hypoglycemia; Insulin; Japanese; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SHORT ACTING INSULIN; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOLOGY; HUMAN; HYPERHIDROSIS; HYPERPHAGIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

EID: 84949217579     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0147-6     Document Type: Article

References (21)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas/6e/diabetes. Accessed 9 Jul 2015.
2. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002;18:S9–13.
3. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev. 2009;25:705–16.
4. Namba M, Katsuno T, Kusunoki Y, Matsuo T, Miuchi M, Miyagawa J. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol. 2012;17:10–5.
5. Japan Diabetes Society. Treatment Guide for Diabetes. 2012–2013 Edited by Japan Diabetes Society. Bunkodo Co. Ltd. http://www.jds.or.jp/modules/en/index.php?content_id=27. Accessed 29 Jul 2015.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.
7. Kadowaki T, Tajima N, Odawara M, Minamide T, Kawashima M, Yanagida D, et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013;4:160–72.
8. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Yang W. An observational non interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries the A1chieve study. Diabetes Res Clin Pract. 2011;94:352–63.
9. Mohamed M. An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies. Curr Med Res Opin. 2008;24:507–14.
10. Noh RM, Graveling AJ, Frier BM. Medically minimizing the impact of hypoglycemia in type 2 diabetes: a review. Expert Opin Pharmacother. 2011;12:2161–75.
11. Graveling AJ, Frier BM. Impaired awareness of hypoglycemia: a review. Diabetes Metab. 2010;36:S64–74.
12. Oishi M, Yamazaki K, Okaguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A, Japan Diabetes Clinical Data Management Study Group. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32). J Diabetes Investig. 2014;5:581–7.
13. Kothny W, Foley JE, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:252–7.
14. Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes. 2013;4:151–6.
15. Ning G, Wang W, Li L, Ma J, Lv X; all investigators, Yang M, Wang W, Woloschak M, Lukashevich V, Kothny W. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes. 2015. doi:10.1111/1753-0407.12303. (Epub ahead of print).
16. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11:1145–52.
17. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513–23.
18. Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study. Diabetes Care. 2013;36:3875–81.
19. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
20. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
21. Ahrén B. Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes. 2014;5:40–51.